ReviewFrontiers in cardiovascular medicine2023
Prevalence, awareness, treatment, and control of dyslipidemia in Chinese adults: a systematic review and meta-analysis.
Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2025Pooled it
- Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis.European journal of medical research · 2025Pooled it
- Pooled it
- Global scientific trends in hypercholesterolemia research from 2003 to 2023: a data-driven bibliometric and visual analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double-Blind, Single-Dose, Parallel-Group Study in Healthy Chinese Participants.Clinical pharmacology in drug development · 2026Trial
- Lipid Metabolism Modulation by a Flavonoid-StandardizedJournal of experimental pharmacology · 2026Trial
- Cost-Effectiveness of Pitavastatin in Dyslipidemia: A Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
- Article
- Gender-specific age inflection points for hypertension, elevated fasting blood glucose, and dyslipidemia in a Northern Chinese cohort: a comorbidity-based analysis.BMC public health · 2026Article
- Association between PMBMC public health · 2026Article
- Physical Activity Modifies the Association between C-Reactive Protein - Triglyceride - Glucose Index (CTI) and Dyslipidemia: Evidence from a 10-Year Chinese Cohort.Journal of sports science & medicine · 2026Article
- Decoding cardiovascular risk in Chinese middle-aged and elderly adults: a 9-year prospective study integrating machine learning with explainable AI based on CHARLS cohort.BMC medical informatics and decision making · 2026Article
- Non-HDL Cholesterol and Residual Cardiometabolic Risk in Middle Eastern Patients with Atherosclerotic Cardiovascular Disease.Healthcare (Basel, Switzerland) · 2026Article
- Simplicity meets accuracy: TyG-Waist as a practical alternative to CVAI for type 2 diabetes prediction in high-risk Chinese adults.BMC endocrine disorders · 2026Article
- Association Between ERBB2 and ERBB3 Polymorphisms and Dyslipidaemia and Serum Lipid Levels in a Chinese Population.Biochemical genetics · 2026Article
- Understanding the link between lipid and ocular disorders for effective therapy.Archives of medical science : AMS · 2026Article
- Prevalence of borderline elevated and elevated cholesterol among new adult patients from 23 hospitals in 12 cities of Jiangsu Province: a multicenter cross-sectional study.Frontiers in nutrition · 2026Article
- Long-term exposure to ambient air pollution and lipid profiles: a longitudinal study in a heavily industrialized region of northern China.Frontiers in public health · 2026Article
- Article
- Effects of altitude and sociodemographic factors on cardiometabolic disorders in the southwestern plateau areas of China.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Researchers have conducted a considerable number of epidemiological studies on dyslipidemia in China over recent years. Nevertheless, a representative study to comprehensively appraise for the epidemiological status of dyslipidemia is still lacked. This meta-analysis is intended to explore the pooled prevalence, rates of awareness, treatment, and control of dyslipidemia among adults in Chinese Mainland. Materials and methods: A systematic review was performed on relevant cross-sectional studies published since January 2012 by searching six authoritative literature databases. Meta-analyses were conducted in included studies based on a random-effect model to summarize the epidemiological status of dyslipidemia in China. A potential source of heterogeneity was detected by subgroup analysis and meta-regression. Publication bias was assessed by Results: Forty-one original researches with a total of 1,310,402 Chinese participants were finally included in the meta-analysis. The prevalence, rates of awareness, treatment, and control of dyslipidemia were 42.1%, 18.2%, 11.6%, and 5.4%, respectively. With a pooled prevalence estimate at 24.5%, low HDL-C was the most prevalent among various dyslipidemia types, followed by hypertriglyceridemia (TG) (15.4%), hypercholesterolemia (TC) (8.3%), and high LDL-C (7.1%). The pooled prevalence of elevated serum lipoprotein(a) [Lp(a)] was 19.4%. By gender, the prevalence of dyslipidemia was 47.3% in males and 38.8% in females. Subgroup analyses revealed that the prevalence in southern and urban areas were higher than their counterparts. Females and population in urban areas tended to possess higher rates of awareness, treatment, and control. Meta-regression analyses suggested that the year of screening influenced prevalence estimates for dyslipidemia. The impact of the study's quality on the pooled estimates is insignificant. Conclusion: Our study suggested a severe epidemic situation of dyslipidemia among adults in Chinese Mainland. More importantly, the awareness, treatment, and control rates were extremely low, revealing that dyslipidemia is a grave health issue. Consequently, we should attach more importance to the management of dyslipidemia, especially in economically underdeveloped areas. Systematic review registration: PROSPERO [CRD42022366456].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.